Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS
Quantum BioPharma Ltd. has taken a significant step towards clinical trials for its oral Lucid-MS treatment for multiple sclerosis by partnering with a leading contract development and manufacturing organization.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a pivotal development in its quest to address multiple sclerosis (MS) through its subsidiary, Huge Biopharma Australia Pty Ltd. The company has entered into an agreement with a leading contract development and manufacturing organization (CDMO) to produce an oral formulation of Lucid-MS for an upcoming Phase 2 clinical trial. This trial aims to evaluate the efficacy of Lucid-MS in restoring mobility in individuals suffering from MS, leveraging over a decade of preclinical studies where the therapy showed promise in enabling animals to regain their ability to walk.
Lucid-MS represents a breakthrough as a patented, first-in-class, non-immunomodulatory neuroprotective compound. It has demonstrated potential in preventing demyelination, a critical factor in MS and other neurodegenerative diseases. The agreement with the CDMO is a crucial milestone towards submitting an Investigational New Drug (IND) application to the FDA for Lucid-21-302 in MS, marking a significant advancement in the treatment landscape for MS patients.
The implications of this development are profound for the MS community, offering hope for a treatment that could potentially reverse the debilitating effects of the disease. With MS affecting millions worldwide, the advancement of Lucid-MS into Phase 2 trials underscores Quantum BioPharma's commitment to addressing unmet medical needs in neurodegenerative diseases. For more details on Quantum BioPharma's innovative approach to MS treatment, visit https://ibn.fm/y8RRY.
Quantum BioPharma's dedication to developing treatments for challenging neurodegenerative and metabolic disorders is further highlighted by its portfolio of innovative assets and biotech solutions. The company's strategic investments and partnerships, including its agreement with Unbuzzd Wellness Inc., reflect its broader mission to impact the biopharmaceutical landscape significantly. For the latest updates on Quantum BioPharma's endeavors, stakeholders can refer to the company's newsroom at https://ibn.fm/QNTM.